Back to Newsroom
Back to Newsroom

Ticker Research Issues Report on VeriTeQ Corporation

Tuesday, 03 March 2015 04:30 PM

Ticker Research

Topic:

ROCHESTER, NY / ACCESSWIRE / March 3, 2015 / Ticker Research, a stock market research firm focused on the small cap and microcap sectors, announced today that it has released a new report on VeriTeQ Corporation. (OTC: VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies.

To view or download the free report, please visit: http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-VTEQD_Research_Report_March_3.pdf.

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. 

VeriTeQ offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.

Below is an excerpt from Ticker Research's report:

"We note that the press release from February 12th, 2015 is a very interesting development for VeriTeQ Corp. Essentially, the term sheet the company has executed gives Establishment Labs, S.A. "EL" the option to exclusively license VeriTeQ's intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market for an upfront license fee of $1.75 million with a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

There are 2 major takeaways investors should monitor based on this news:

1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.

2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."

About VeriTeQ 

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com

More information on VTEQD can be found at http://www.veriteqcorp.com/.

About Ticker Research: 

Ticker Research provides research reports for microcap companies. Ticker Research produces sponsored and non-sponsored small cap and micro cap stock research reports and articles.

This Ticker Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures and disclaimers before investing. Ticker Research is not a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.tickerresearch.com.

Ticker Research 

[email protected]

SOURCE: Ticker Research

Topic:
Back to newsroom
Back to Newsroom
Share by: